KR910004181A - 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태 - Google Patents

생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태 Download PDF

Info

Publication number
KR910004181A
KR910004181A KR1019900011979A KR900011979A KR910004181A KR 910004181 A KR910004181 A KR 910004181A KR 1019900011979 A KR1019900011979 A KR 1019900011979A KR 900011979 A KR900011979 A KR 900011979A KR 910004181 A KR910004181 A KR 910004181A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
prosobel
natural protein
dosage forms
Prior art date
Application number
KR1019900011979A
Other languages
English (en)
Inventor
브쟝꽁 데니
마끄 애아슈 쟝
뒤푸 알랭
시그로 파브릭
Original Assignee
꼴레트 베지니에
라보라뚜아레 들라그랑주
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 꼴레트 베지니에, 라보라뚜아레 들라그랑주 filed Critical 꼴레트 베지니에
Publication of KR910004181A publication Critical patent/KR910004181A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

내용 없음.

Description

생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 순수한 옥소디핀(분말) 및 옥소디핀/폴리비닐피롤리돈 공침전물의 고체 용액내 옥소디핀에 대해 사람의 체내로 흡수된 활성 성분의 비율을 표시한 것이다.
제2도는 여러 투여 형태를 투여한 후 3시간에 해당하는 결과를 표시한 것이다.
제3도는 여러 투여 형태에 기초한 생체내 용해의 동역학(kinetics)을 표시한 것이다.

Claims (16)

10-70 중량%의 천연 단백질을 불활성 부형제에 함침시키는 것으로 구성된, 경구용 의약품의 생체내 유효성을 조절하는 방법.
제1항에 있어서, 천연 단백질이 우유로 부터 추출되는 방법.
제1항 또는 제2항에 있어서, 천연 단백질이 PROSOBEL인 방법.
칼슘 억제제로서 작용하는 최소한 하나의 활성 성분, 일반적인 부형제 및 천연 단백질로 구성되며 조절된 생체내 유효성을 지닌 제약학적 조성물.
제4항에 있어서, 칼슘 억제제가 디하이드로피리딘인 제약학적 조성물.
제4항 또는 제5항에 있어서, 활성 성분이 옥소디딘인 제약학적 조성물.
제4항 또는 제5항에 있어서, 활성 성분이 니페디핀인 제약학적 조성물.
제4항 내지 제7항의 어느 한 항에 있어서, 천연 단백필이 우유로부터 추출된 제약학적 조성물.
제4항 내지 제8항의 어느 한 항에 있어서, 천연 단백질이 PROSOBEL인 제약학적 조성물.
제4항, 제5항, 제6항, 제8항 또는 제9항의 어느 한 항에 있어서 옥소디핀과 PROSOBEL L60을 함유하는 제약학적 조성물.
제4항, 제5항, 제6항, 제8항 또는 제9항의 어느 한 항에 있어서, 옥소디핀과 PROSOBEL L85를 함유하는 제약학적 조성물.
제4항, 제5항, 제7항, 제8항 또는 제9항의 어느 한 항에 있어서, 니페디핀과 PROSOBEL L60를 함유한 제약학적 조성물.
제4항, 제5항, 제7항, 제8항 또는 제9항의 어느 한 항에 있어서, 니페디핀과 PROSOBEL L85를 함유하는 제약학적 조성물.
제4항 내지 제13항의 어느 한 항에 있어서, 일일단위 투여량을 함유한 경질 젤라틴 캡슐에 들어있는 제약학적 조성물.
제4항 내지 제13항의 어느 한 항에 있어서, 일일단위 투여량을 함유한 정제 형태인 제약학적 조성물.
제15항에 있어서, 정제가 두개의 층, 즉 빠르게 방출되는 충전량을 함유하는 하나의 층과 서서히 방출되는 다른 하나의 층으로 된 제약학적 조성물.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900011979A 1989-08-07 1990-08-04 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태 KR910004181A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8910605A FR2650502B1 (fr) 1989-08-07 1989-08-07 Nouvelle forme galenique orale ameliorant la biodisponibilite
FR89-10605 1989-08-07

Publications (1)

Publication Number Publication Date
KR910004181A true KR910004181A (ko) 1991-03-28

Family

ID=9384532

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900011979A KR910004181A (ko) 1989-08-07 1990-08-04 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태

Country Status (25)

Country Link
EP (1) EP0412877A1 (ko)
JP (1) JPH0377819A (ko)
KR (1) KR910004181A (ko)
CN (1) CN1049455A (ko)
AU (1) AU631235B2 (ko)
CA (1) CA2022447A1 (ko)
CS (1) CS276556B6 (ko)
DD (1) DD297332A5 (ko)
DE (1) DE4023136A1 (ko)
FI (1) FI903885A0 (ko)
FR (1) FR2650502B1 (ko)
GB (1) GB2234898A (ko)
HU (1) HU204997B (ko)
IE (1) IE902629A1 (ko)
IL (1) IL95105A0 (ko)
IN (1) IN170789B (ko)
LU (1) LU87777A1 (ko)
MA (1) MA21923A1 (ko)
NO (1) NO903442L (ko)
NZ (1) NZ234593A (ko)
OA (1) OA09301A (ko)
PE (1) PE491A1 (ko)
PT (1) PT94823A (ko)
TN (1) TNSN90111A1 (ko)
ZA (1) ZA905886B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701815B1 (de) * 1992-01-17 1999-06-30 ALFATEC-PHARMA GmbH Verfahren zur Herstellung von Wirkstoff enthaltenden Pulvern, Granulaten oder Pellets mit einem Gerüst aus hydrophilen Makromolekülen und ihre Verwendung
DE4221880A1 (de) * 1992-07-03 1994-01-05 Alfatec Pharma Gmbh Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen
KR20030089147A (ko) * 2002-05-16 2003-11-21 슈라펫 주식회사 애완동물용 급수통

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE854414C (de) * 1949-04-26 1952-11-04 Dieter Dr Med Ellenbeck Verfahren zur Herstellung von injizierbaren Loesungen von an sich mehr oder weniger schwer loeslichen Arzneimitteln
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3015611A (en) * 1959-08-25 1962-01-02 Nysco Lab Inc Low density whey-bound tablets
GB1063872A (en) * 1962-08-11 1967-03-30 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical compositions
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE3250023T (ko) * 1981-01-14 1990-03-29
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4670251A (en) * 1984-05-30 1987-06-02 Igene Biotechnology, Inc. Microcrystalline tableting excipient derived from whey
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
CA1324083C (en) * 1987-03-09 1993-11-09 Tetsu Miyoshi Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
DE3881615T2 (de) * 1987-09-08 1993-09-23 Takeda Chemical Industries Ltd Wasserunloesliche cytokine.

Also Published As

Publication number Publication date
TNSN90111A1 (fr) 1991-03-05
DE4023136A1 (de) 1991-02-14
AU631235B2 (en) 1992-11-19
DD297332A5 (de) 1992-01-09
CN1049455A (zh) 1991-02-27
HUT55230A (en) 1991-05-28
GB2234898A (en) 1991-02-20
CA2022447A1 (fr) 1991-02-08
LU87777A1 (fr) 1990-12-11
NO903442L (no) 1991-02-08
AU6023990A (en) 1991-02-07
PT94823A (pt) 1991-04-18
NO903442D0 (no) 1990-08-06
OA09301A (fr) 1992-09-15
IN170789B (ko) 1992-05-23
MA21923A1 (fr) 1991-04-01
FR2650502A1 (fr) 1991-02-08
NZ234593A (en) 1993-04-28
CS383890A3 (en) 1992-06-17
HU204997B (en) 1992-03-30
GB9017144D0 (en) 1990-09-19
IL95105A0 (en) 1991-06-10
FR2650502B1 (fr) 1994-05-27
JPH0377819A (ja) 1991-04-03
HU904909D0 (en) 1991-01-28
EP0412877A1 (fr) 1991-02-13
FI903885A0 (fi) 1990-08-06
PE491A1 (es) 1991-01-26
CS276556B6 (en) 1992-06-17
IE902629A1 (en) 1991-02-27
ZA905886B (en) 1991-04-24

Similar Documents

Publication Publication Date Title
KR880003617A (ko) 경구용 고형제형과 그의 제조방법
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
KR970064599A (ko) 서방성 제형
DE69928554D1 (de) Therapeutische formulierung enthaltende dosierungsform
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
DE3872739T2 (de) Arzneimittel mit langsamer freisetzung.
KR830005854A (ko) 알카리성 진통제 캡슐의 제조방법
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
KR850700109A (ko) 항 이뇨제 ddavp 및 그의 제조 방법
KR940021054A (ko) 캡슐형 유비데카레논 경구 제제
KR960000217A (ko) L- 카르니틴염과 이를 함유한 조성물
RU2003100507A (ru) Фармацевтические композиции
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
KR880007073A (ko) 의 약 품
RU2000114174A (ru) Применение фосфолипидных комплексов экстрактов из vitis vinifera в качестве противоатеросклеротических агентов
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
KR910004181A (ko) 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
MD1504F2 (ro) Aplicare a dimeticonei în calitate de ingredient activ în compoziţie farmaceutică pentru tratamentul aftelor şi stomatitelor şi compoziţie farmaceutică conţinând dimeticonă
JPS59204116A (ja) ビタミン組成物
KR910004190A (ko) 온단세트론의 신규 의학 용도
ES2043567T1 (es) Una composicion farmaceutica de liberacion controlada para uso oral que contiene farmacos anti-inflamatorios no esteroideos.
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid